Editorial Board ::: Clinical Cancer Drugs

ISSN: 2212-6988 (Online)
ISSN: 2212-697X (Print)


Volume 4, 2 Issues, 2017


Download PDF Flyer




Clinical Cancer Drugs

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Giulio Francia
The University of Texas
El Paso, TX
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Editor-in-Chief:

Giulio Francia (Biography
Giulio Francia

Dr. Francia began his career by undertaking a PhD with Dr. Ian Hart at the Imperial Cancer Research Fund in London, UK, which has since evolved into Cancer UK. After his PhD, he trained with Dr. Robert Kerbel in Toronto, Canada, on aspects of metastasis, therapies for metastatic disease, and tumor resistance to therapy. He is now Assistant Professor at The University of Texas at El Paso, where he is attempting to set up a research program that is internationally recognized for pioneering new cancer therapeutic ideas, and for generating in vivo models to help translate laboratory findings into the clinic - by developing new metastatic tumor models, and by refining those he has already established.

)

The University of Texas
El Paso, TX
USA



Co-Editor:

Ronit Satchi-Fainaro (Biography
Ronit Satchi-Fainaro

Prof. Ronit Satchi-Fainaro (Ph.D.) is Head of the Cancer Angiogenesis & Nanomedicine Laboratory; Chair of the Department of Physiology & Pharmacology, Sackler Faculty of Medicine, serves on the Preclinical Dekanat of the Faculty of Medicine, is President of the Israeli Society of Controlled Release and is Chair of IAUCC. Prof. Satchi-Fainaro received her Bachelor of Pharmacy from the Hebrew University, Israel (1995) and her Ph.D. from the University of London, UK (1999). She then spent two years as postdoctoral fellow at Harvard University and Children’s Hospital Boston working with Judah Folkman on novel angiogenesis-targeted nanomedicines. In 2003, she was appointed Instructor in Surgery at Boston Children’s Hospital and Harvard Medical School and continued to have a Visiting Associate Professor position there till 2011. She joined Tel Aviv University in 2006.

)

Tel Aviv University
Tel Aviv
Israel


Associate Editors:

J.M.L. Ebos
Roswell Park Cancer Institute
Buffalo, NY
USA

K.X. Sun (Biography
K.X. Sun

Dr Xueying Sun obtained MD and PhD from Shandong University in 1994. He is currently holding a professorial position at the Department of Surgery, the Affiliated Hospital of Harbin Medical University, and a position of Honorary Senior Research Fellow at Department of Molecular Medicine & Pathology, FMHS, University of Auckland. His present research and professional specialities include tumor hypoxia, cancer molecular targeted therapy, cellular signalling and non-coding RNAs. He was a winner of World Health Organization Fellowship (1999-2000) and Wellcome Trust Leave Fellowship (2001-2005). He has published over 200 research articles in peer-viewed journals including 120 articles in Science Citation Index journals. He is also a member of Editorial board of five academic journals, and a member of the review panels for National Natural Scientific Foundation, Ministry of Science and Technology and Ministry of Education of China.

)

Harbin Medical University
Harbin
China

D. Fan (Biography
D. Fan

Professor Daiming Fan is the member and vice president of Chinese Academy of Engineering, foreign associate of the USA National Academy of Medicine, past president of Fourth Military Medical University, past president of Chinese Society of Gastroenterology, director of Xijing Hospital of Digestive Diseases, and director of State Key Laboratory of Cancer Biology. He is now the vice president of Chinese Anti-Cancer Association, and vice president of Asian Pacific Association of Gastroenterology. As the congress president, he successfully organized the GASTRO2013 (WCOG/APDW) in Shanghai. He was the first awardee of the Prize “French National Academy of Medicine-Servier”.

)

Fourth Military Medical University
Xi'an
China

G.M. Pitari
Thomas Jefferson University
Philadelphia, PA
USA


Regional Editors:

Region: Europe
G. Bocci (Biography
G. Bocci

Dr. Bocci is a professor of Pharmacology at the University of Pisa. He obtained the degree of Medicine (1995), the degree of Clinical Pharmacology (1999) and a PhD in Pharmacology (2003) from the University of Pisa. Dr. Bocci was post-doctoral fellow for 3 years at the University of Toronto. Dr. Bocci is PI of projects granted by international associations, foundations and pharmaceutical companies. He is member of ASCO and AACR. He is author of more than 130 scientific papers published on international journals, 11 chapters on books, and 5 patents. He is regional editor of Clinical Cancer Drugs from the foundation of the journal.

)

University of Pisa
Pisa
Italy
T. Robak (Biography
T. Robak

Tadeusz Robak MD., Ph.D. is Professor of Hematology at the Medical University of Lodz, Poland. He currently holds the posts of Professor of Hematology at the Medical University of Lodz and Chief of Department of Hematology at the Copernicus Memorial Hospital in Lodz, Poland. The particular research emphasis has been on the application of new drugs in the treatment of leukemia multiple myeloma and lymphoma and interactions of antineoplastic agents. Professor Robak published more than 550 journal articles, 480 abstracts and 25 books and chapters. He received award “Eminent Scientist of the Year 2010” from International Research Promotion Council (IRPC).

)

Medical University of Lodz
Lodz
Poland
Region: USA
N.S. Yee (Biography
N.S. Yee

Dr. Yee obtained a medical doctorate (M.D.) and a doctorate (Ph.D.) in Molecular Biology from Cornell University. Currently, Dr. Yee is an Assistant Professor of Medicine in Hematology and Oncology in the Pennsylvania State University College of Medicine. He is also a medical oncologist in the PennState Cancer Institute, and an attending and consultant physician in the PennState Milton S. Hershey Medical Center. He has published extensively in basic, translational, and clinical sciences, including original research articles, review articles, book chapters, and clinical case reports. Dr. Yee is currently the Regional Editor of this journal (Clinical Cancer Drugs), published by Bentham Science Publishers.

)

Penn State Hershey Cancer Institute
Hershey, PA
USA

Editorial Board Members:

N. Andre (Biography
N. Andre

Nicolas André is at Inserm UMR_S 911, Centre de Recherche en Oncologie biologique et Oncopharmacologie, 27 Boulevard Jean Moulin, Faculté de Pharmacie, Aix-Marseille Université; Service d'Hématologie & Oncologie Pédiatrique, AP-HM; and the Metronomics Global Health Initiative, 13005 Marseille, France. Nicolas André is an Associate Professor in the Department of Paediatric Oncology and Haematology in the Hôpital pour Enfants de La Timone, AP-HM, and in the Faculty of Medicine, Aix Marseille University, France. He is also coordinates the early phase trials in paediatric cancers. He co-founded the Metronomic Global Health Initiative in 2010. His research interests and topics include rare paediatric tumours, paediatric brain tumours and pharmacology (new anticancer agents, metronomic chemotherapy, drug repositioning, microtubule-targeting agents), and global oncology.

)

Children Hospital of "La Timone"
Marseille
France

G.-Q. Chen
Shanghai Jiao Tong University
Shanghai
China

A. Di Paolo (Biography
A. Di Paolo

Antonello Di Paolo received his MD (1992) and degree in Pharmacology (2000) from the University of Pisa, Italy, while he gained his PhD (1997) at the Superior School of University Studies in Pisa. Currently, Antonello Di Paolo is associate professor of Pharmacology at the University of Pisa and physician at the Unit of Clinical Pharmacology and Pharmacogenetics, Civil Hospital, Pisa. His main research is focused on pharmacokinetics and pharmacogenetics of anticancer agents, with special interest in fluoropirimidines in colorectal cancers, small tyrosine kinase inibitors and immunomodulating agents in hematological malignancies. He is authors of more than 100 articles published on indexed international journals.

)

University of Pisa
Pisa
Italy

J. Fidler
University of Texas
Houston , TX
USA

M. Hajduch
Palacky University and University Hospital Olomouc
Olomouc
Czech Republic

J. Li
Fudan University Cancer Center
Shanghai
China

D. Marchetti
Baylor College of Medicine
Houston, TX
USA

R.J. Nicholas
Virginia Cancer Specialists
Fairfax, VA
USA

J.W. Park
University of California
San Francisco, CA
USA

E. Segal (Biography
E. Segal

Received her MD from Necker Hospital (Paris Descartes University, France) and her PhD in Molecular and cellular Biology from Pierre and Marie Curie University (Paris, France). After working in Molecular and Biological Pharmacology in Gustave-Roussy Institute (Villejuif, France), she obtained a position as a research scientist at CNRS. She joined Saint-Louis Hospital (Paris, France) in 1998 where she became a team leader as a Research Director working on the pharmacological and physiological regulation of the telomerase expression and activity in an INSERM Unit. She joined Paris Descartes University in 2010 where she became the head of INSERM UMR-S 1007 named "Cellular Homeostasis and Cancer".

)

Paris Descartes University
Saints-Peres, Paris
France

H. Tang (Biography
H. Tang

Dr. Tang obtained his Medical Doctor Degree and Ph.D. in Pathogen Biology from Tianjin Medical University, and gained postdoctoral training in Harvard University and HHMI. He was a faculty member in Harvard Medical School and Fudan University. Currently Dr. Tang is a Professor and Chair of Tianjin Life Science Research Center and Department of Pathogen Biology, Tianjin Medical University. Dr. Tang has focused on the regulation of non-coding RNA on tumorigenesis and viral proliferation. He has published more than 100 research articles and served as an editor of more than 10 journals.

)

Tianjin Medical University
Tianjin
China

P. de Souza
University of Western Sydney
Sydney
Australia

A. Bardelli (Biography
A. Bardelli

Full Professor at Dept. of Oncology, University of Torino, Director of the Laboratory of Molecular Oncology and deputy Director of the Candiolo Cancer Institute-IRCCS, Torino, Italy. As a postdoc at the Johns Hopkins University he performed the first comprehensive mutational profile of protein and lipid kinases in colorectal cancers (CRC). As an independent investigator Prof Bardelli translated these findings into clinical practice by unveiling the molecular landscape of response and resistance to EGFR, HER2 and BRAF blockade in CRC. He recently developed innovative blood-based tests (liquid biopsies) to monitor patient’s response during treatment. A future focus of his lab is to study how the emergence and evolution of drug-resistant clones can be restrained to improve the efficacy of anticancer agents, that is to develop therapies that adapt to tumor’s evolution. Prof Bardelli has been listed in the Thomson Reuters List of Highly Cited Researchers. He is the author of over 150 peer-reviewed manuscripts (H factor 68).

)

University of Torino
Torino
Italy

J.CS. Chim (Biography
J.CS. Chim

Prof James CS Chim is a clinician scientist interested in the multiple myeloma. He is a Member of the International Myeloma Working Group, Executive Council Member of the Asian Myeloma Network, Founding member of the International Academy of Clinical Hematology (IACH) & Founding Chairman of the Hong Kong Society of Myeloma. He has published in excess of 240 articles in peer-reviewed journals including Blood, Leukemia and Journal of Clinical Oncology.

)

Queen Mary Hospital
Hong Kong
China

Q. P. Dou (Biography
Q. P. Dou

Dr. Q. Ping Dou is Professor of Oncology, Pharmacology and Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI. He obtained his B.S. degree in chemistry from Shandong University in 1981, Ph.D. degree in chemistry from Rutgers University in 1988, and postdoctoral training at Dana-Farber Cancer Institute and Harvard Medical School from 1988 to 1993. Dr. Dou has extensive experience in the fields of molecular targeting, drug discovery, chemoprevention, natural products, proteasome inhibitors, cell cycle and apoptosis, and has published ~222 peer-reviewed research and review articles, many of those in journals of the highest quality.

)

Wayne State University
Detroit, MI
USA

C. Funes
Hospital Universitario 12 de Octubre
Madrid
Spain

J. Ho (Biography
J. Ho

Dr. James Ho is an Associate Professor and Honorary Consultant at the Department of Medicine, Queen Mary Hospital, The University of Hong Kong (HKU). He received his medical degree (M.B.,B.S.) in 1993 and M.D. in 2007 from HKU, with training in internal medicine and respiratory medicine. He is FCCP and FRCP (Edin, Lond and Glasg). Dr. Ho has an established track record in lung cancer research, and the areas of focus over the years include preclinical models, the role of antioxidants, epidemiology, diagnostics, and clinical trials. He has published more than 90 papers in peer-reviewed journals.

)

The University of Hong Kong
Hong Kong
China

P. Limonta (Biography
P. Limonta

Dr. Limonta obtained a Degree in Pharmaceutical Chemistry and Technology and a Degree in Pharmacy from the University of Milano, Italy. She also holds a Postdoctoral Degree in Pharmacology and a Postdoctoral Degree in Experimental Endocrinology from the University of Milano, Italy. She has been Postdoctoral fellow in Biology of Reproduction at the Population Council, Center for Biomedical Research, New York (1983-1984). Currently, Dr. Limonta is Associate Professor of Applied Biology, at the University of Milano. She has published 90 scientific peer-reviewed publications, most of them in the field of molecular oncology. She is currently Editorial Advisory board Member of the journal 'Clinical Cancer Drugs'.

)

University of Milan
Milan
Italy

H. Nagai
Toho University Omori Medical Center
Tokyo
Japan

P. Nowak-Sliwinska (Biography
P. Nowak-Sliwinska

Prof. Patrycja Nowak-Sliwinska joined the School of Pharmaceutical Sciences of the University of Geneva in June 2016. She is a head of Molecular Pharmacology Group and with her team she currently works, in a close collaboration engineers and with clinical partners, on personalized optimization of multi-drug combinations for cancer treatment.

)

University Hospital Lausanne (CHUV)
Lausanne
Switzerland

T. Pitts (Biography
T. Pitts

Todd Pitts is an Assistant Professor at the University of Colorado Denver Anschutz Medical Campus. He earned his PhD in Medical and Surgical Oncology and Clinical Immunology at the Second University of Naples. Todd Pitts’ research is focused on pre-clinical studies of novel, targeted therapies for the treatment of advanced colorectal and pancreatic cancer, utilizing both in vitro cell culture models and in vivo mouse model systems. These studies serve as a rational basis for therapeutic treatment choices for patients with advanced GI cancers in the Cancer Center’s Phase I Clinical Trials Program.

)

University of Colorado School of Medicine
Aurora, CO
USA

S.Y. Sun (Biography
S.Y. Sun

Dr. Shi-Yong Sun is a tenured Professor in the Department of Hematology and Medical Oncology in the Emory University School of Medicine and Winship Cancer Institute in Atlanta, Georgia, USA. Dr. Sun’s research primarily focuses on regulation of death receptors, particularly TRAIL receptors, by small therapeutic molecules and their implications in drug-induced apoptosis and cancer therapy. In addition, his lab is interested in understanding mTOR signaling in cancer and targeting the mTOR axis for cancer therapy. Dr. Sun is a Georgia Research Alliance Distinguished Cancer Scientist and Halpern Research Scholar. He has published over 150 papers in prominent peer-reviewed journals.

)

Emory University
Atlanta, GA
USA

B.M. Veneziani
University of Naples Federico II - Medical School
Naples
Italy

J. Brabek (Biography
J. Brabek

Jan Brábek is an Associate Professor at Charles University and BIOCEV and a principal investigator of laboratory of Cancer Cell Invasion. His areas of expertise are individual cancer cell invasiveness (molecular and cellular mechanisms of mesenchymal and amoeboid invasiveness, invasive structures – podosomes, invadopodia) and integrin-mediated Src signalling (signalling through FAK/Src and p130CAS, regulation of Src and its signalling), phosphoproteomics of Src-transformed cells. He is a member of the Invadosome Consortium, in 2006 he received an Award of the League Against Cancer.

)

Charles University
Prague
Czech Republic

S. Cos Corral (Biography
S. Cos Corral

Samuel Cos, M.D. in 1983 and Ph.D. in 1986, is Full Professor and Head in the Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Spain. For over 30 years, Dr. Cos’s research has focused on the oncostatic actions of melatonin, particularly in breast cancer. He has published over 100 journal articles, book chapters and reviews on this topic. His research has been supported by Spanish and European funding agencies. He currently serves on the editorial boards of the Clinical Cancer Drugs, Journal of Tumor and Dataset Papers in Medicine: Oncology.

)

University of Cantabria
Cantabria
Spain

U. Emmenegger (Biography
U. Emmenegger

Dr. Urban Emmenegger obtained his medical degree from the University of Bern/Switzerland, followed by training in Internal Medicine and Medical Oncology, and research training in tumor biology, with special emphasis on tumor angiogenesis and metronomic chemotherapy. Currently, Dr. Emmenegger is appointed as Staff Medical Oncologist and Scientist at Odette Cancer Centre & Sunnybrook Research Institute, and is Assistant Professor in the Department of Medicine, all at the University of Toronto/Canada. Dr. Emmenegger is specialized in the treatment of advanced prostate cancer, a disease which is also at the center of his research interests. He is particularly interested in improving the use of metronomic chemotherapy for prostate cancer, in understanding therapeutic resistance, and identifying predictive biomarkers.

)

Sunnybrook Health Sciences Centre
Toronto
Canada

A.W. Griffioen (Biography
A.W. Griffioen

Dr. Griffioen obtained his PhD in immunology and medicine from the Utrecht University, The Netherlands. He is Being trained and formally registered as an immunologist, dr Griffioen’s research interest is in vascular biology and angiogenesis. He is currently professor of experimental oncology and angiogenesis and is heading the Angiogenesis Laboratory at the VU University Medical Center in Amsterdam. Dr. Griffioen has published over 220 scientific publications, is inventor on 20 patents and is the founding Editor-in-Chief of the journal Angiogenesis (1997).

)

VU University Medical Center
Amsterdam
The Netherlands

Y. Imai (Biography
Y. Imai

Dr. Imai graduated from Tokyo University, got a M.D. license in 1988, and given a title of Ph.D. from Tokyo University, Graduate School of Medicine in 1998. Presently, he is a full professor of Department of Diagnostic Pathology, Dokkyo Medical University, in Tochigi, Japan. His research interest exists in anatomic/molecular pathology, gastroenterology, oncology, cancer chemotherapy, and molecular biology. He once performed an intensive research on drug resistance caused by ABC transporters. He is presently exploring molecular markers for the best tailor-made therapies for gastrointestinal cancers.

)

Dokkyo Medical University Koshigaya Hospital
Koshigaya
Japan

S.E. Lipshultz
Wayne State University
Detroit, MI
USA

G. Natale (Biography
G. Natale

Gianfranco Natale is associate professor of Human Anatomy at the University of Pisa. He obtained the degree of Medicine (1990) and the degree of Clinical Pharmacology (2004) from the University of Pisa. He participated in the organization of scientific congresses and exhibitions. He is author of more than 80 scientific papers published on international journals, 20 chapters on books, and 1 book. He is director of the Museum of Human Anatomy “Filippo Civinini” of the University of Pisa and he is interested in the history of medicine.

)

University of Pisa
Pisa
Italy

W.K. Oh (Biography
W.K. Oh

William K. Oh is Chief of the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, and Associate Director of Clinical Research at the Tisch Cancer Institute, both in New York. He is a Professor of Medicine and Urology and holds the Ezra M. Greenspan, MD, Chair in Clinical Cancer Therapeutics at Mount Sinai. His research interests include the development of novel therapeutics and blood biomarkers for prostate cancer.

)

Mount Sinai School of Medicine
New York, NY
USA

D. Santini
University Campus Bio-Medico
Rome
Italy

Y.J. Surh (Biography
Y.J. Surh

Professor Young-Joon Surh is currently Director of Tumor Microenvironment Global Core Research Center, Seoul National University, Korea. He graduated from Seoul National University, and earned a PhD degree at the University of Wisconsin-Madison. After postdoctoral training at the Massachusetts Institute of Technology, he was appointed as Assistant Professor at Yale University School of Medicine. He is currently Associate Editor of Molecular Carcinogenesis, Toxicology & Applied Pharmacology, Free Radical Research, and Frontiers in Nutrition, and Editorial Board member of Antioxidants & Redox Signaling, International Journal of Cancer, Mutation Research, Life Sciences, Food and Chemical Toxicology, Precision Oncology (Nature Publishing Group), etc.

)

Seoul National University
Seoul
South Korea

M.C. Yergeri
Dr. Bhanuben Nanavati College of Pharmacy
Mumbai
India












Advertisement

Related Journals




Related eBooks



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science